Back to Authors

Lystig, Ted

Mayo Clinic

tEidos Therapeutics, affiliate of BridgeBio Pharma, San Francisco, California, US

Citations 1

A plain language review of the ATTRibute-CM study: efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy

Future Cardiology | December 12, 2025 | Volume: 21 | Issue: 12 | Pages: 1017-1025

10.1080/14796678.2025.2591426 | PMID 41384357